An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Willingness to try new drugs for obesity management have propelled the growth of this market, which today is almost five ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

Mounjaro side effect explained as more than 220,000 Brits are expected to receive the drug over the next three years ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...